Phase 3 Trials of Baricitinib Disappoint in SL Despite the encouraging phase II trial results of baricitinib in SLE patients, two parallel phase III trials have failed to redemonstrate the efficacy of baricitinib in active SLE. https://t.co/JjouppdG8k https://t.co/SHATPuTIiP